Battelle Places Order with Instem for Provantis Preclinical and submit-SEND Software Solutions
19 July 2011
Instem Life Science Systems plc
("Instem", the "Company" or the "Group")
Battelle Places Order with Instem for Provantis Preclinical and submit-SEND Software Solutions
Instem Solutions to Automate Full Range of R&D Processes
Instem Life Science Systems plc (AIM: INS.L), a leading provider of software applications to the global early development healthcare market, announced today that Battelle has purchased its Provantis® and submit™ preclinical software solutions to automate processes within its preclinical facilities.
Battelle is the world’s largest independent research and development organisation. Battelle’s health and life science capabilities support development, delivery, testing, and evaluation of innovative solutions for the biotech, pharmaceutical, and agrochemical industries and government agencies.
Provantis is a modern, fully integrated software system for single users and global organisations engaged in preclinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, Provantis streamlines processes and workflows with straightforward, intuitive functionality for simple or complex studies within a GLP or non-GLP environment, on-site or over the Web.
Part of the Centrus solution suite, Instem’s submit™ software supports the US food and Drug Administration (FDA) sponsored Standard for Exchange of Nonclinical Data (SEND) initiative. Submit is the only fully integrated solution in production today for companies using SEND for the exchange, review and submission of research data. Converting data from any source system into SEND files, submit allows sponsors, contract research organisations and regulators to share, visualise and analyse study data more efficiently.
Phil Reason, CEO of Instem, commented, “We are delighted to have secured this contract with Battelle, the world’s largest independent research and development organisation. This is a strong competitive win for Provantis and an excellent early win for our newly launched Centrus suite. We continue to win the majority of new business placed in the early development healthcare market and look to the future with confidence.”
For further information, please contact:
| Instem plc | www.instem.com |
| Phil Reason, CEO | +44 (0) 1785 825600 |
| Nigel Goldsmith, CFO | |
| N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| Richard Lindley | |
| Nick Owen | |
| James White | |
| Wallbrook Financial PR | Tel: +44 (0) 20 7933 8000 |
| Paul Cornelius | or instem@walbrookpr.com |
| Sam Allen | |
| Helen Cresswell | |
| Paul Whittington |
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.